NASDAQ: NBTX
Nanobiotix Sa Stock Forecast, Predictions & Price Target

Analyst price target for NBTX

Based on 1 analyst offering 12 month price targets for Nanobiotix Sa

Min Forecast
$26.00+7.79%
Avg Forecast
$26.00+7.79%
Max Forecast
$26.00+7.79%

Should I buy or sell NBTX stock?

Based on 1 analyst offering ratings for Nanobiotix Sa.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NBTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NBTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NBTX stock forecasts and price targets.

NBTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-06

1 of 1

Forecast return on equity

Is NBTX forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is NBTX forecast to generate an efficient return on assets?

Company
-16.28%
Industry
115.15%
NBTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NBTX earnings per share forecast

What is NBTX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.87
Avg 2 year Forecast
-$0.25
Avg 3 year Forecast
-$0.26

NBTX revenue forecast

What is NBTX's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$70.2M+487.13%
Avg 2 year Forecast
$43.2M+261.41%
Avg 3 year Forecast
$73.8M+517.19%
NBTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NBTX revenue growth forecast

How is NBTX forecast to perform vs Biotechnology companies and vs the US market?

Company
73.45%
Industry
118.19%
Market
23.42%
NBTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NBTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NBTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NBTX$24.12$26.00+7.79%Strong Buy
DAWN$11.23$25.60+127.96%Strong Buy
SEPN$26.34$33.83+28.45%Strong Buy
XERS$6.91$10.80+56.30%Buy
CMPX$6.44$15.50+140.68%Strong Buy

Nanobiotix Sa Stock Forecast FAQ

Is Nanobiotix Sa Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NBTX) stock is to Strong Buy NBTX stock.

Out of 1 analyst, 1 (100%) are recommending NBTX as a Strong Buy, 0 (0%) are recommending NBTX as a Buy, 0 (0%) are recommending NBTX as a Hold, 0 (0%) are recommending NBTX as a Sell, and 0 (0%) are recommending NBTX as a Strong Sell.

If you're new to stock investing, here's how to buy Nanobiotix Sa stock.

What is NBTX's earnings growth forecast for 2026-2028?

(NASDAQ: NBTX) Nanobiotix Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.

Nanobiotix Sa's earnings in 2026 is -$60,756,470.On average, 7 Wall Street analysts forecast NBTX's earnings for 2026 to be -$41,821,194, with the lowest NBTX earnings forecast at -$48,217,376, and the highest NBTX earnings forecast at -$32,415,043. On average, 6 Wall Street analysts forecast NBTX's earnings for 2027 to be -$11,933,752, with the lowest NBTX earnings forecast at -$37,344,831, and the highest NBTX earnings forecast at $29,376,133.

In 2028, NBTX is forecast to generate -$12,507,769 in earnings, with the lowest earnings forecast at -$51,844,774 and the highest earnings forecast at $29,790,968.

What is NBTX's revenue growth forecast for 2026-2028?

(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of 73.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.42%.

Nanobiotix Sa's revenue in 2026 is $11,950,588.On average, 7 Wall Street analysts forecast NBTX's revenue for 2026 to be $3,384,526,021, with the lowest NBTX revenue forecast at $709,079,064, and the highest NBTX revenue forecast at $5,986,653,238. On average, 6 Wall Street analysts forecast NBTX's revenue for 2027 to be $2,083,390,057, with the lowest NBTX revenue forecast at $567,263,251, and the highest NBTX revenue forecast at $3,615,049,071.

In 2028, NBTX is forecast to generate $3,557,840,380 in revenue, with the lowest revenue forecast at $197,963,298 and the highest revenue forecast at $7,664,807,022.

What is NBTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NBTX) forecast ROA is -16.28%, which is lower than the forecast US Biotechnology industry average of 115.15%.

What is NBTX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NBTX price target, the average NBTX price target is $26.00, with the highest NBTX stock price forecast at $26.00 and the lowest NBTX stock price forecast at $26.00.

The Wall Street analyst predicted that Nanobiotix Sa's share price could reach $26.00 by Feb 6, 2027. The average Nanobiotix Sa stock price prediction forecasts a potential upside of 7.79% from the current NBTX share price of $24.12.

What is NBTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NBTX) Nanobiotix Sa's current Earnings Per Share (EPS) is -$1.28. On average, analysts forecast that NBTX's EPS will be -$0.87 for 2026, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$0.67. On average, analysts forecast that NBTX's EPS will be -$0.25 for 2027, with the lowest EPS forecast at -$0.77, and the highest EPS forecast at $0.61. In 2028, NBTX's EPS is forecast to hit -$0.26 (min: -$1.07, max: $0.62).

What is NBTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NBTX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.